Ticker Launch
Sign inTry it free

SPAC · Deal announced · DMAA

Drugs Made In America Acquisition Corp.

Business combination with Power Analytics Global Corp

Drugs Made In America Acquisition Corp. (DMAA) is a blank-check company (SPAC) that raised $200M in its initial public offering on Jan 29, 2025, listing on Nasdaq. It agreed to combine with Power Analytics Global Corp, announced on Apr 29, 2026, at a stated value of $2.85B. The deal has not closed yet. Clear Street led the IPO. Maples and Calder advised the SPAC and Winston & Strawn advised the underwriters on the IPO.

AI, advanced analytics and quantum-resistant security solutions

Status
Deal announced
Ticker
DMAA
IPO date
Jan 29, 2025
IPO size
$200M
IPO exchange
Nasdaq
Target
Power Analytics Global Corp
Target sector
AI/Software
Announced
Apr 29, 2026
Stated deal value
$2.85B
IPO underwriters
Clear Street
SPAC counsel (IPO)
Maples and Calder
Underwriters' counsel (IPO)
Winston & Strawn

More on this SPAC for subscribers

Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.

Try it free for 7 daysOpen in Ticker Launch

Then $99/month or $999/year. Cancel anytime.

Filings

Other pending SPAC mergers